Perbedaan Eterindo Wahanatama Tbk dan Organon Pharma Indonesia Tbk.: Eterindo Wahanatama Tbk diperdagangkan di Rp70 (kapitalisasi pasar 326,81 M), sedangkan Organon Pharma Indonesia Tbk. diperdagangkan di Rp29.000 (kapitalisasi pasar 104,4 M). Perbedaan utamanya: Eterindo Wahanatama Tbk jauh lebih besar — sekitar 3,1× kapitalisasi pasar Organon Pharma Indonesia Tbk.. Mana yang lebih baik tergantung tujuan investasimu.
| ETWA | SCPI | |
|---|---|---|
Kapitalisasi Pasar | 326,81 M | 104,4 M |
Imbal hasil berjalan pada periode standar
Berita terbaru kedua aset
PT Eterindo Wahanatama Tbk or Eterindo is the parent company to midstream specialty chemical companies, interrelated by ownership and through both vertical and horizontal integration. Eterindo has established itself as one of the largest producers of specialty in South East Asia. The products are used as raw material in the production of paints, coatings, adhesives and similar consumer product realm. The breadth of its range gives Eterindo a distinct edge over its competitors.Presently, Eterindo is among the largest producers of plasticizers, an important raw material for producing cables, footwear, tyres and other basic consumer goods, near to one daily usage in life. Modern production facilities, state of the art technology and a highly trained and dedicated labour force means Eterindo companies will continue to offer high quality at competitive prices, to customers at home and overseas. In recognition of its technical achievement, Eterindo has been awarded ISO 9002 certification. Strategic partnership have been formed with multinationals, including Mitsui & Co. Ltd. Of Japan, Kyowa Hakko Kogyo Co. Ltd., Mitsui Bussan Solvent & Coating Co., Ltd., Daewoo Group of Korea and state owned company PT Petrokimia Gresik.
Selengkapnya di halaman ETWA →PT Merck Sharp Dohme Pharma Tbk was established within the frame work of the Foreign Capital Investment Law No. 1 year 1967 as amended by Law No. 11 year 1970 based on Notarial Deed No. 17 dated 7 March 1972 of Djojo Muljadi, S.H. The company originally incorporated as PT. Essex Indonesia, as a joint venture between Schering Corporation, a worldwide, research-based pharmaceutical enterprise headquartered in the United States, and an Indonesian businessman.
Selengkapnya di halaman SCPI →